A
Austin Goetz
Researcher at Thomas Jefferson University
Publications - 8
Citations - 711
Austin Goetz is an academic researcher from Thomas Jefferson University. The author has contributed to research in topics: Pancreatic cancer & KRAS. The author has an hindex of 4, co-authored 8 publications receiving 435 citations. Previous affiliations of Austin Goetz include Albert Einstein Medical Center & Yeshiva University.
Papers
More filters
Journal ArticleDOI
Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
Hervé Tiriac,Pascal Belleau,Dannielle D. Engle,Dennis Plenker,Astrid Deschênes,Tim D.D. Somerville,Fieke E. M. Froeling,Richard A. Burkhart,Robert E. Denroche,Gun-Ho Jang,Koji Miyabayashi,C. Megan Young,C. Megan Young,Hardik Patel,Michelle Ma,Joseph F. LaComb,Randze Lerie Palmaira,Ammar A. Javed,Jasmine Huynh,Molly E. Johnson,Kanika Arora,Nicolas Robine,Minita Shah,Rashesh Sanghvi,Austin Goetz,Cinthya Y. Lowder,Laura A. Martello,Else Driehuis,Nicolas Lecomte,Gokce Askan,Christine A. Iacobuzio-Donahue,Hans Clevers,Laura D. Wood,Ralph H. Hruban,Elizabeth D. Thompson,Andrew J. Aguirre,Brian M. Wolpin,Aaron R. Sasson,Joseph Kim,Maoxin Wu,Juan Carlos Bucobo,Peter J. Allen,Divyesh V. Sejpal,William Nealon,James Sullivan,Jordan M. Winter,Phyllis A. Gimotty,Jean L. Grem,Dominick J. DiMaio,Jonathan M. Buscaglia,Paul M. Grandgenett,Jonathan R. Brody,Michael A. Hollingsworth,Grainne M. O'Kane,Faiyaz Notta,Edward J. Kim,James M. Crawford,Craig Devoe,Allyson J. Ocean,Christopher L. Wolfgang,Kenneth H. Yu,Ellen Li,Christopher R. Vakoc,Benjamin Hubert,Sandra Fischer,Sandra Fischer,Julie M. Wilson,Richard A. Moffitt,Jennifer J. Knox,Alexander Krasnitz,Steven Gallinger,Steven Gallinger,Steven Gallinger,David A. Tuveson +73 more
TL;DR: A pancreatic cancer patient-derived organoid (PDO) library is generated that recapitulates the mutational spectrum and transcriptional subtypes of primary Pancreatic cancer and proposes that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection.
Journal ArticleDOI
CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype
Shruti Lal,Edwin C. Cheung,Mahsa Zarei,Ranjan Preet,Saswati N. Chand,Nicole C. Mambelli-Lisboa,Carmella Romeo,Matthew C. Stout,Eric Londin,Austin Goetz,Cinthya Y. Lowder,Avinoam Nevler,Charles J. Yeo,Paul M. Campbell,Jordan M. Winter,Dan A. Dixon,Jonathan R. Brody +16 more
TL;DR: The notion that targeting HuR is a promising therapeutic strategy to treat GI malignancies is supported, as CRISPR/Cas9 technology was successfully used to delete the HuR gene in both PDA and colorectal cancer cell lines.
Journal ArticleDOI
Abemaciclib is effective against pancreatic cancer cells and synergizes with HuR and YAP1 inhibition
Teena Dhir,Christopher W. Schultz,Aditi Jain,Samantha Z. Brown,Alex Haber,Austin Goetz,Chun-Hua Xi,Gloria H. Su,Liang Xu,James Posey,Wei Jiang,Charles J. Yeo,Talia Golan,Talia Golan,Michael J. Pishvaian,Jonathan R. Brody +15 more
TL;DR: The data suggest that abemaciclib may be therapeutically relevant for the treatment in PDAC, especially as part of a combination regimen inhibiting YAP1 or HuR and siRNA oligonucleotides targeted against HuR, Yap1, and their common target cyclin D1, validated the synergy studies.
Journal ArticleDOI
The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria.
Christopher W. Schultz,Grace A. McCarthy,Teena Nerwal,Avinoam Nevler,James B. DuHadaway,Matthew McCoy,Wei Jiang,Samantha Z Brown,Austin Goetz,Aditi Jain,Valerie S. Calvert,Vikalp Vishwakarma,Dezhen Wang,Ranjan Preet,Joel Cassel,Ross Summer,Hoorah Shaghaghi,Yves Pommier,Simone A Baechler,Michael J. Pishvaian,Talia Golan,Talia Golan,Charles J. Yeo,Emanuel F. Petricoin,George C. Prendergast,Joseph M. Salvino,Pankaj K. Singh,Dan A. Dixon,Jonathan R. Brody +28 more
TL;DR: The antihelminthic pyrvinium pamoate (PP) has been shown to cause PDAC cell death, although the mechanism has not been fully determined.
Journal ArticleDOI
A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2
Avinoam Nevler,Alexander J. Muller,Alexander J. Muller,Joseph A. Cozzitorto,Austin Goetz,Jordan M. Winter,Theresa P. Yeo,Harish Lavu,Charles J. Yeo,George C. Prendergast,George C. Prendergast,Jonathan R. Brody +11 more
TL;DR: Future studies will evaluate the value of IDO2 genotyping as a prognostic, early detection marker for pancreatic ductal adenocarcinoma and a predictive marker for novel immune checkpoint therapies.